These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 22412142

  • 21. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
    Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C.
    Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
    [Abstract] [Full Text] [Related]

  • 22. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 23. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.
    Chen MC, Chiang FF, Wang HM.
    Neoplasma; 2013 Dec; 60(5):561-7. PubMed ID: 23790176
    [Abstract] [Full Text] [Related]

  • 24. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR, Eng C.
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [Abstract] [Full Text] [Related]

  • 25. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF.
    Clin Cancer Res; 2010 Jun 01; 16(11):3078-87. PubMed ID: 20395213
    [Abstract] [Full Text] [Related]

  • 26. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, Xu F, Yassine M.
    Clin Colorectal Cancer; 2011 Dec 01; 10(4):333-9. PubMed ID: 22000810
    [Abstract] [Full Text] [Related]

  • 27. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.
    Crit Rev Oncol Hematol; 2011 Jun 01; 78(3):243-51. PubMed ID: 20619672
    [Abstract] [Full Text] [Related]

  • 28. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
    Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ.
    J Clin Oncol; 2013 Jul 01; 31(19):2477-84. PubMed ID: 23690424
    [Abstract] [Full Text] [Related]

  • 29. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
    Douillard JY, Zemelka T, Fountzilas G, Barone C, Schlichting M, Heighway J, Eggleton SP, Srimuninnimit V.
    Clin Colorectal Cancer; 2014 Mar 01; 13(1):14-26.e1. PubMed ID: 24370353
    [Abstract] [Full Text] [Related]

  • 30. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.
    Oncologist; 2012 Mar 01; 17(1):13. PubMed ID: 22210086
    [Abstract] [Full Text] [Related]

  • 31. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.
    J Clin Oncol; 2014 Jul 20; 32(21):2240-7. PubMed ID: 24687833
    [Abstract] [Full Text] [Related]

  • 32. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB, Wang Q, Hu WG.
    World J Gastroenterol; 2015 Apr 14; 21(14):4365-72. PubMed ID: 25892888
    [Abstract] [Full Text] [Related]

  • 33. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 34. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
    Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR.
    J Clin Oncol; 2010 Nov 01; 28(31):4747-54. PubMed ID: 20921467
    [Abstract] [Full Text] [Related]

  • 35. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB.
    J Clin Oncol; 2010 Sep 20; 28(27):4240-6. PubMed ID: 20713879
    [Abstract] [Full Text] [Related]

  • 36. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 37. Standard chemotherapy with cetuximab for treatment of colorectal cancer.
    Li XX, Liang L, Huang LY, Cai SJ.
    World J Gastroenterol; 2015 Jun 14; 21(22):7022-35. PubMed ID: 26078581
    [Abstract] [Full Text] [Related]

  • 38. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Samonigg H, Hoefler G.
    J Clin Pathol; 2014 Mar 14; 67(3):198-203. PubMed ID: 24098024
    [Abstract] [Full Text] [Related]

  • 39. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 40. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
    Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F.
    J Clin Oncol; 2010 Mar 01; 28(7):1181-9. PubMed ID: 20100964
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.